Xeris Biopharma Inc. (XERS)
Xeris Biopharma Statistics
Share Statistics
Xeris Biopharma has 153.94M shares outstanding. The number of shares has increased by 3.83% in one year.
| Shares Outstanding | 153.94M |
| Shares Change (YoY) | 3.83% |
| Shares Change (QoQ) | 3.26% |
| Owned by Institutions (%) | 43.96% |
| Shares Floating | 141.93M |
| Failed to Deliver (FTD) Shares | 21.84K |
| FTD / Avg. Volume | 0.74% |
Short Selling Information
The latest short interest is 17.04M, so 11.07% of the outstanding shares have been sold short.
| Short Interest | 17.04M |
| Short % of Shares Out | 11.07% |
| Short % of Float | 11.33% |
| Short Ratio (days to cover) | 3.93 |
Valuation Ratios
The PE ratio is -9.07 and the forward PE ratio is 34.25. Xeris Biopharma's PEG ratio is 0.51.
| PE Ratio | -9.07 |
| Forward PE | 34.25 |
| PS Ratio | 2.45 |
| Forward PS | 1.3 |
| PB Ratio | -16.8 |
| P/FCF Ratio | -13.15 |
| PEG Ratio | 0.51 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Xeris Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of -9.17.
| Current Ratio | 1.67 |
| Quick Ratio | 1.19 |
| Debt / Equity | -9.17 |
| Debt / EBITDA | -19.4 |
| Debt / FCF | -7.17 |
| Interest Coverage | -1.1 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $515.41K |
| Profits Per Employee | $-139.18K |
| Employee Count | 394 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | -2.27M |
| Effective Tax Rate | 3.97% |
Stock Price Statistics
The stock price has increased by 136.21% in the last 52 weeks. The beta is 0.89, so Xeris Biopharma's price volatility has been higher than the market average.
| Beta | 0.89 |
| 52-Week Price Change | 136.21% |
| 50-Day Moving Average | 4.41 |
| 200-Day Moving Average | 3.34 |
| Relative Strength Index (RSI) | 40.61 |
| Average Volume (20 Days) | 2.96M |
Income Statement
In the last 12 months, Xeris Biopharma had revenue of 203.07M and earned -54.84M in profits. Earnings per share was -0.37.
| Revenue | 203.07M |
| Gross Profit | 166.24M |
| Operating Income | -33.65M |
| Net Income | -54.84M |
| EBITDA | -13.99M |
| EBIT | -26.62M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
The company has 71.62M in cash and 271.45M in debt, giving a net cash position of -199.83M.
| Cash & Cash Equivalents | 71.62M |
| Total Debt | 271.45M |
| Net Cash | -199.83M |
| Retained Earnings | -671.86M |
| Total Assets | 323.06M |
| Working Capital | 67.22M |
Cash Flow
In the last 12 months, operating cash flow was -36.98M and capital expenditures -868K, giving a free cash flow of -37.85M.
| Operating Cash Flow | -36.98M |
| Capital Expenditures | -868K |
| Free Cash Flow | -37.85M |
| FCF Per Share | -0.26 |
Margins
Gross margin is 81.86%, with operating and profit margins of -16.57% and -27%.
| Gross Margin | 81.86% |
| Operating Margin | -16.57% |
| Pretax Margin | -28.12% |
| Profit Margin | -27% |
| EBITDA Margin | -6.89% |
| EBIT Margin | -16.57% |
| FCF Margin | -18.64% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for XERS is $6, which is 46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6 |
| Price Target Difference | 46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.7 |
| Piotroski F-Score | 5 |